Avadel Pharmaceuticals plc

(NASDAQ:AVDL)

Latest On Avadel Pharmaceuticals plc (AVDL):

Date/Time Type Description Signal Details
2023-05-17 12:48 ESTNewsAvadel Pharmaceuticals: Lumryz Approved, Launch Expected June 2023 And We Remain BullishN/A
2023-05-04 21:04 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.48 misses by $0.10N/A
2023-05-03 19:46 ESTNewsAvadel Pharmaceuticals' Strategic Moves To Conquer The Narcolepsy Market (Rating Upgrade)N/A
2023-05-01 18:02 ESTNewsAvadel gains 12% as FDA issues final approval for sleep therapyN/A
2023-04-19 19:06 ESTNewsAvadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz LaunchN/A
2023-04-01 06:51 ESTNewsAvadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Call TranscriptN/A
2023-03-30 23:36 ESTNewsAvadel Pharmaceuticals prices ADSs and Series B preferred shares offeringN/A
2023-03-30 23:36 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.44 misses by $0.17N/A
2023-03-29 23:23 ESTNewsAvadel Pharma enters into royalty agreement with RTW investments for up to $75MN/A
2023-03-22 22:21 ESTNewsAvadel stock rises on FDA nod to import sleep disorder drug Lumryz ahead of potential approvalN/A
2023-03-12 15:40 ESTNewsAvadel Pharmaceuticals: Real-World Data Supports Market Opportunity For LumryzN/A
2023-03-07 14:48 ESTNewsNavigating Avadel's Potential And Risks With LumryzN/A
2023-03-02 11:50 ESTNewsAvadel requests final FDA approval for Lumyrz in narcolepsyN/A
2023-03-02 11:50 ESTNewsSenators introduce legislation to eliminate drug company loophole that delays competitionN/A
2023-02-25 02:43 ESTNewsAvadel seeks full FDA approval for sleep therapy as Jazz loses patent appealN/A
2022-12-09 12:50 ESTNewsAvadel And Jazz: The Oxybate Wars - Duking It OutN/A
2022-12-07 06:29 ESTNewsAvadel: Lumryz Overhang Now Removed, Rate BuyN/A
2022-11-30 11:51 ESTNewsAvadel surges 13% as Jefferies upgrades on opportunity to dent Jazz's market shareN/A
2022-11-19 02:02 ESTNewsAvadel Pharmaceuticals jumps on patent win in dispute with Jazz Pharma (update)N/A
2022-11-11 23:25 ESTNewsAvadel at eight-month high as FTC comments raise prospects for lead drugN/A
2022-11-09 18:40 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.33 misses by $0.07N/A
2022-11-09 18:40 ESTNewsAvadel Pharmaceuticals plc (AVDL) Q3 2022 Earnings Call TranscriptN/A
2022-10-05 16:44 ESTNewsENPH, ATHX and AVDL among mid-day moversN/A
2022-09-06 20:37 ESTNewsAvadel's LUMRYZ: A Good Night's Sleep For Narcolepsy PatientsN/A
2022-09-05 11:33 ESTNewsAvadel Pharmaceuticals: Navigating Through The UncertaintyN/A
2022-09-01 00:30 ESTNewsAvadel Pharmaceuticals filed for 500M mixed shelf offeringN/A
2022-08-25 23:39 ESTNewsAvadel gains as judge delays hearing on patent dispute with Jazz PharmaN/A
2022-08-10 10:51 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 16:29 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$1.07 misses by $0.66N/A
2022-08-08 16:19 ESTNewsAvadel Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-19 12:00 ESTNewsAvadel stock rises 8% as FDA grants tentative approval to its Jazz's sleep disorder drug rivalN/A
2022-06-30 04:47 ESTNewsAvadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023N/A
2022-06-17 06:54 ESTNewsAvadel: Further Delay, But Some Light At The End Of The TunnelN/A
2022-06-02 01:57 ESTNewsAvadel Pharmaceuticals reports insider transactions from Director, CEO & CFON/A
2022-05-27 14:51 ESTNewsAvadel spikes as Oppenheimer says selloff is overdoneN/A
2022-05-26 23:13 ESTNewsAvadel stock falls 26% as FDA cites patent issue in sleep disorder drug FT218 filing; expects tentative approval in 2023N/A
2022-05-26 23:13 ESTNewsJazz Pharmaceuticals benefitting from Avadel's daytime sleepiness drug delayN/A
2022-05-10 00:19 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.45 misses by $0.02N/A
2022-05-10 00:19 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-27 02:01 ESTNewsAvadel shares surge as company comments on recent trading activityN/A
2022-04-06 10:44 ESTNewsAvadel reports publication of data showing benefits of sleep disorder drug FT218N/A
2022-03-22 13:38 ESTNewsAvadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To SleepinessN/A
2022-03-18 08:57 ESTNewsAvadel Pharmaceuticals GAAP EPS of -$0.38 beats by $0.03N/A
2022-03-18 08:57 ESTNewsAvadel Pharmaceuticals plc's (AVDL) CEO Gregory Divis on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-12 00:29 ESTNewsAvadel posts new efficacy and safety data for lead candidate in narcolepsyN/A
2021-11-09 01:43 ESTNewsAvadel Pharmaceuticals EPS beats by $0.01N/A
2021-11-09 01:43 ESTNewsAvadel records rising costs in Q3 amid plans to launch narcolepsy therapyN/A
2021-11-09 01:43 ESTNewsAvadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-05 19:20 ESTNewsAvadel Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-01 13:34 ESTNewsAvadel Pharmaceuticals: I Am HoldingN/A

About Avadel Pharmaceuticals plc (AVDL):

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Quotes by TradingView

See Advanced Chart

General

  • Name Avadel Pharmaceuticals plc
  • Symbol AVDL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 32
  • Fiscal Year EndDecember
  • IPO Date1996-06-07
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.avadel.com
View More

Valuation

  • Trailing PE 71.85
  • Price/Sales (Trailing 12 Mt.) 11.79
  • Price/Book (Most Recent Quarter) 2.73
  • Enterprise Value Revenue 16.33
  • Enterprise Value EBITDA 37.99
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.32
  • Next Year EPS Estimate -$0.14
  • Next Quarter EPS Estimate -$0.25
  • Profit Margin 31%
  • Operating Margin -164%
  • Return on Assets -10%
  • Return on Equity 11%
  • Revenue 22.33 million
  • Earnings Per Share $0.13
  • Revenue Per Share $0.42
  • Gross Profit 16.59 million
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 546.06 million
  • EBITDA -38869000
  • PEG Ratio 0.07
  • Analyst Target Price $18.56
  • Book Value Per Share $2.78
View More

Share Statistics

  • Shares Outstanding 58.47 million
  • Shares Float 42.53 million
  • % Held by Insiders 589%
  • % Held by Institutions 56.94%
  • Shares Short 4.58 million
  • Shares Short Prior Month 3.77 million
  • Short Ratio 6.04
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 1.47
  • 52 Week High $12
  • 52 Week Low $4.83
  • 50 Day Moving Average 8.46
  • 200 Day Moving Average 6.8
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Avadel Pharmaceuticals plc (AVDL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Avadel Pharmaceuticals plc (AVDL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$N/A-$0.19-$0.2830.91%
2020-09-302020-11-09$N/A-$0.20-$0.2518.37%
2020-06-302020-08-10$N/A$0.49-$0.10578.05%
2020-03-312020-05-11$12.24 million-$0.02-$0.2391.21%
2019-12-312020-03-12$11 million-$0.07-$0.2672.73%
2019-09-302019-11-12$14.23 million-$0.24-$0.2711.11%
2019-06-302019-08-09$17.55 million-$0.23-$0.2920.69%
2019-03-312019-05-08$16.44 million-$0.35-$0.4928.57%
2018-12-312019-03-15$20.92 million-$1.72-$2.3426.5%
2018-09-302018-11-05$19.83 million-$0.43-$0.36-21.13%
2018-06-302018-08-07$29.23 million-$0.09-$0.3271.88%
2018-03-312018-05-02$33.29 million-$0.32-$0.3713.51%
2017-12-312018-03-08$34.41 million-$0.24-$0.3735.14%
2017-09-302017-11-08$39.68 million$0.52-$0.023071.43%
2017-06-302017-08-08$45.21 million$0.68$0.09684.31%
2017-03-312017-05-09$52.51 million$0.59$0.11436.36%
2016-12-312017-03-07$43.09 million$0.11-$0.37129.73%
2016-09-302016-11-07$32.09 million-$0.54-$0.23-134.78%
2016-06-302016-08-08$38.86 million-$0.48$0.06-900%
2016-03-312016-05-09$36.22 million-$0.15$0.14-207.14%
2015-12-312016-03-10$44.57 million$1.75$0.091844.44%
2015-09-302015-11-12$47.31 million-$0.73$0.23-417.39%
2015-06-302015-07-30$48.6 million-$0.43$0.40-207.5%
2015-03-312015-05-15$32.53 million$0.27$0.31-12.9%
2014-12-312015-03-19$2.97 million-$0.69-$0.17-305.88%
2014-09-302014-10-31$2.91 million-$0.26-$0.12-116.67%
2014-06-302014-07-29$4.32 million-$0.13-$0.09-44.44%
2014-03-312014-05-12$4.58 million-$0.60-$0.15-300%
2013-12-312014-03-06$6.18 million$0.20-$0.16225%
2013-09-302013-10-31$5.58 million-$0.25-$0.20-25%
2013-06-302013-07-29$5.54 million-$1.21-$0.27-348.15%
2013-03-312013-05-07$5.14 million-$0.35-$0.33-6.06%
2012-12-312013-02-28$7.31 million$0.46-$0.19342.11%
2012-09-302012-11-05$5.4 million-$0.26-$0.19-36.84%
2012-06-302012-07-25$6.03 million$0.25-$0.08412.5%
2012-03-312012-05-07$7.36 million-$0.19-$0.07-171.43%
2011-12-312012-03-14$8.65 million-$0.08$0.10-180%
2011-09-302011-11-02$10.43 million$0.07-$0.09177.78%
2011-06-302011-07-25$6.75 million-$0.14-$0.09-55.56%
2011-03-312011-05-09$6.76 million-$0.20-$0.11-81.82%
2010-12-312011-03-03$13.45 million$0.11$0.05120%
2010-09-302010-11-04$8.04 million-$0.14
2010-06-302010-07-28$7.52 million-$0.18-$0.05-260%
2010-03-312010-05-05$8.09 million-$0.17-$0.13-30.77%
2009-12-312010-03-08$10.59 million-$0.23-$0.10-130%
2009-09-302009-11-16$9.9 million-$0.14-$0.09-55.56%
2009-06-302009-08-05$9.58 million-$0.15-$0.10-50%
2009-03-312009-05-11$12.05 million$0.05-$0.14135.71%
2008-12-312009-03-04$9.47 million-$0.11-$0.02-450%
2008-09-302008-11-03$9.14 million-$0.10-$0.1741.18%
2008-06-302008-08-06$9.15 million-$0.14-$0.2544%
2008-03-312008-05-13$10.87 million-$0.15-$0.2948.28%
2007-12-312008-03-03$10.56 million-$0.23-$0.3330.3%
2007-09-302007-10-30$9.02 million-$0.38-$0.417.32%
2007-06-302007-08-01$7.45 million-$0.57-$0.28-103.57%
2007-03-312007-05-07$9.63 million-$0.38-$0.33-15.15%
2006-12-312007-03-07$7.78 million-$0.25-$0.3732.43%
2006-09-302006-11-01$5.41 million-$0.43-$0.38-13.16%
2006-06-302006-07-31$4.74 million-$0.40-$0.33-21.21%
2006-03-312006-05-03$5.1 million-$0.41-$0.31-32.26%
2005-12-312006-03-07$6.26 million-$0.28-$0.3417.65%
2005-09-302005-10-26$3.09 million-$0.50-$0.37-35.14%
2005-06-302005-07-27$6.14 million-$0.41-$0.39-5.13%
2005-03-312005-05-05$8.11 million$0.01-$0.03133.33%
2004-12-312005-03-11$18.72 million$0.28$0.31-9.68%
2004-09-302004-10-28$13.35 million$0.12$0.119.09%
2004-06-302004-07-29$8.99 million-$0.07$0.07-200%
2004-03-312004-04-29$14.35 million$0.18$0.03500%
2003-12-312004-03-11$11.27 million$0.08$0.04100%
2003-09-302003-10-30$5.37 million-$0.11$0.05-320%
2003-06-302003-07-30$5 million-$0.10$0.02-600%
2003-03-312003-04-30$3.53 million-$0.10$0.03-433.33%
1998-12-311999-02-23-$0.12-$0.10-20%
1998-09-301998-10-27-$0.17-$0.13-30.77%
1998-06-301998-07-31-$0.22-$0.18-22.22%
1997-12-311998-03-17$0.00-$0.15100%
1997-06-301997-07-31-$0.22-$0.248.33%
1996-12-311997-03-26-$0.15-$0.1816.67%

Avadel Pharmaceuticals plc (AVDL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Avadel Pharmaceuticals plc (AVDL) Chart:

Avadel Pharmaceuticals plc (AVDL) News:

Below you will find a list of latest news for Avadel Pharmaceuticals plc (AVDL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Avadel Pharmaceuticals plc (AVDL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-03-202.513.1CALL0 00TRUE00
2026-03-2050CALL0 00TRUE00
2026-03-207.50CALL0 00TRUE00
2026-03-20108.4CALL0 00TRUE00
2026-03-2012.56.9CALL0 470TRUE00
2026-03-20156.6CALL0 8980TRUE00
2026-03-2017.53.7CALL0 100TRUE00
2026-03-20201.66CALL0 7940TRUE00
2026-03-2022.50.05CALL0 261910.16FALSE00
2026-03-20250.5CALL0 7627.91FALSE00
2026-03-20301.8CALL0 1053.8FALSE00
2026-03-20350.05CALL0 9073.73FALSE00
2026-03-202.50.05PUT0 0329.65FALSE00
2026-03-2050PUT0 0223.32FALSE00
2026-03-207.50.17PUT0 1164.07FALSE00
2026-03-20100.58PUT0 10122.7FALSE00
2026-03-2012.50.05PUT0 5090.59FALSE00
2026-03-20150.01PUT0 19263.98FALSE00
2026-03-2017.50.05PUT0 81540.71FALSE00
2026-03-20200.05PUT0 209718.98FALSE00
2026-03-2022.51.5PUT0 53037.84TRUE00
2026-03-20253.79PUT0 17112.48TRUE00
2026-03-20300PUT0 0103.9TRUE00
2026-03-20350PUT0 0132.47TRUE00
2026-06-182.50CALL0 00TRUE00
2026-06-1850CALL0 00TRUE00
2026-06-187.50CALL0 00TRUE00
2026-06-18100CALL0 00TRUE00
2026-06-1812.50CALL0 00TRUE00
2026-06-18150CALL0 030.12TRUE00
2026-06-1817.54.2CALL0 144.16TRUE00
2026-06-18201.7CALL0 60TRUE00
2026-06-1822.50.05CALL0 14284.5FALSE00
2026-06-18250.01CALL0 9710.72FALSE00
2026-06-18300.01CALL0 522.45FALSE00
2026-06-18350.01CALL0 5039.18FALSE00
2026-06-182.50PUT0 0178.66FALSE00
2026-06-1850PUT0 0121.22FALSE00
2026-06-187.50PUT0 089.22FALSE00
2026-06-18100PUT0 066.89FALSE00
2026-06-1812.50PUT0 049.56FALSE00
2026-06-18150.01PUT0 6435.21FALSE00
2026-06-1817.50.09PUT0 6022.68FALSE00
2026-06-18200.01PUT0 154711.02FALSE00
2026-06-1822.51.55PUT0 63022.35TRUE00
2026-06-18253.97PUT0 38163.23TRUE00
2026-06-18300PUT0 060.13TRUE00
2026-06-18350PUT0 076.6TRUE00
2026-09-1812.50CALL0 00TRUE00
2026-09-18150CALL0 00TRUE00
2026-09-1817.54.2CALL0 00TRUE00
2026-09-18201.7CALL0 233.22TRUE00
2026-09-1822.50.05CALL0 3162.66FALSE00
2026-09-18250CALL0 090.56FALSE00
2026-09-18300CALL0 0109.26FALSE00
2026-09-1812.50.01PUT0 1038.23FALSE00
2026-09-18150.01PUT0 527.3FALSE00
2026-09-1817.50.01PUT0 11517.78FALSE00
2026-09-18200.04PUT0 108.48FALSE00
2026-09-1822.51.5PUT0 2518.27TRUE00
2026-09-18250PUT0 049.85TRUE00
2026-09-18300PUT0 048.28TRUE00
2027-01-152.50CALL0 00TRUE00
2027-01-15516.5CALL0 00TRUE00
2027-01-157.513.9CALL0 540TRUE00
2027-01-151011.6CALL0 40TRUE00
2027-01-1512.59.1CALL0 1140TRUE00
2027-01-15156.7CALL0 320TRUE00
2027-01-1517.54.1CALL0 140TRUE00
2027-01-15201.5CALL0 30123.32TRUE00
2027-01-1522.50.05CALL0 28001.2FALSE00
2027-01-15250.01CALL0 6177.71FALSE00
2027-01-15300.05CALL0 4116.49FALSE00
2027-01-15350.1CALL0 1423.17FALSE00
2027-01-152.50PUT0 0110.52FALSE00
2027-01-1550PUT0 475.24FALSE00
2027-01-157.50.1PUT0 1155.6FALSE00
2027-01-15100.15PUT0 341.91FALSE00
2027-01-1512.51.95PUT0 831.29FALSE00
2027-01-15153.79PUT0 100022.51FALSE00
2027-01-1517.50.01PUT0 45014.85FALSE00
2027-01-15200.05PUT0 21477.75FALSE00
2027-01-1522.51.5PUT0 5215.91TRUE00
2027-01-15254PUT0 38941.84TRUE00
2027-01-15300PUT0 041.29TRUE00
2027-01-153512PUT0 1052.38TRUE00

Latest AVDL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST300$2.245
Jun 13, 2022 7:59 PM EST360$2.245
Jun 13, 2022 7:59 PM EST140$2.245
Jun 13, 2022 7:59 PM EST634$2.245
Jun 13, 2022 7:59 PM EST2$2.25

Avadel Pharmaceuticals plc (AVDL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920080648/0001104659-20-080648-index.htm
2020-02-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1012477/000000000020001346/0000000000-20-001346-index.htm
2020-05-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1012477/000000000020004060/0000000000-20-004060-index.htm
2019-11-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000091068019000084/0000910680-19-000084-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000091957420001139/0000919574-20-001139-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247719000012/0001012477-19-000012-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000007/0001012477-20-000007-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000009/0001012477-20-000009-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1012477/000101247720000013/0001012477-20-000013-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919062085/0001104659-19-062085-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919066833/0001104659-19-066833-index.htm
2019-12-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919068803/0001104659-19-068803-index.htm
2019-12-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919069621/0001104659-19-069621-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919069622/0001104659-19-069622-index.htm
2019-12-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070110/0001104659-19-070110-index.htm
2019-12-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070118/0001104659-19-070118-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070213/0001104659-19-070213-index.htm
2019-12-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000110465919070217/0001104659-19-070217-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919071189/0001104659-19-071189-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919072792/0001104659-19-072792-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465919073238/0001104659-19-073238-index.htm
2020-01-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920001912/0001104659-20-001912-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920003111/0001104659-20-003111-index.htm
2020-02-05S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1012477/000110465920010987/0001104659-20-010987-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020153/0001104659-20-020153-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020407/0001104659-20-020407-index.htm
2020-02-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920020410/0001104659-20-020410-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920024077/0001104659-20-024077-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920032146/0001104659-20-032146-index.htm
2020-03-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920037990/0001104659-20-037990-index.htm
2020-04-16PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920047632/0001104659-20-047632-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920051182/0001104659-20-051182-index.htm
2020-04-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920051350/0001104659-20-051350-index.htm
2020-04-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920051827/0001104659-20-051827-index.htm
2020-04-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920053562/0001104659-20-053562-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920053569/0001104659-20-053569-index.htm
2020-05-01S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1012477/000110465920055587/0001104659-20-055587-index.htm
2020-05-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1012477/000110465920058802/0001104659-20-058802-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920059095/0001104659-20-059095-index.htm
2020-06-16DEFR14ARevised definitive proxy soliciting materialshttps://www.sec.gov/Archives/edgar/data/1012477/000110465920073527/0001104659-20-073527-index.htm
2020-06-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1012477/000110465920076183/0001104659-20-076183-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920080648/0001104659-20-080648-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920082927/0001104659-20-082927-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920091513/0001104659-20-091513-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920092424/0001104659-20-092424-index.htm
2020-08-208-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920097315/0001104659-20-097315-index.htm
2020-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920100190/0001104659-20-100190-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1012477/000110465920104616/0001104659-20-104616-index.htm
2019-12-093Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012565/0001179110-19-012565-index.htm
2019-12-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012567/0001179110-19-012567-index.htm
2019-12-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911019012826/0001179110-19-012826-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008889/0001179110-20-008889-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008890/0001179110-20-008890-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008891/0001179110-20-008891-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008892/0001179110-20-008892-index.htm
2020-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020008893/0001179110-20-008893-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009023/0001179110-20-009023-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009024/0001179110-20-009024-index.htm
2020-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009084/0001179110-20-009084-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009086/0001179110-20-009086-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009461/0001179110-20-009461-index.htm
2020-09-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009462/0001179110-20-009462-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009709/0001179110-20-009709-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009877/0001179110-20-009877-index.htm
2020-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-09-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000117911020009897/0001179110-20-009897-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000119380520000194/0001193805-20-000194-index.htm
2020-03-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000121390020005412/0001213900-20-005412-index.htm
2019-12-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000149315219019859/0001493152-19-019859-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1012477/000149315220002411/0001493152-20-002411-index.htm
2019-11-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021621/0001567619-19-021621-index.htm
2019-11-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021625/0001567619-19-021625-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021875/0001567619-19-021875-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021885/0001567619-19-021885-index.htm
2019-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2020-02-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1012477/999999999520000371/9999999995-20-000371-index.htm
2020-05-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1012477/999999999520001129/9999999995-20-001129-index.htm

Avadel Pharmaceuticals plc (AVDL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Avadel Pharmaceuticals plc (AVDL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 589%
Institutional Ownership: 5694%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-08-13THOMAS S MCHUGHChief Financial OfficerBuy10,000.007.7877,814.0010,000.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009086/0001179110-20-009086-index.htm
2020-09-16Mark Anthony McCamishDirectorBuy118,602.005.73679,968.99118,602.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-09-17Mark Anthony McCamishDirectorBuy52,398.005.83305,249.79171,000.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009879/0001179110-20-009879-index.htm
2020-08-28THOMAS S MCHUGHChief Financial OfficerBuy7,500.006.7750,776.5017,500.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009462/0001179110-20-009462-index.htm
2020-09-18THOMAS S MCHUGHChief Financial OfficerBuy4,000.006.0024,000.0021,500.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009897/0001179110-20-009897-index.htm
2019-11-15Geoffrey Michael GlassDirectorBuy5,000.004.9924,950.0032,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2019-12-03Linda PalczukDirectorBuy7,500.005.9144,325.0035,400.00https://www.sec.gov/Archives/edgar/data/1012477/000110465919070213/0001104659-19-070213-index.htm
2019-11-15Eric J EndeDirectorBuy10,000.004.9849,762.0037,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021875/0001567619-19-021875-index.htm
2020-08-14Linda PalczukDirectorBuy2,500.007.9419,849.7537,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009084/0001179110-20-009084-index.htm
2019-12-04Eric J EndeDirectorBuy10,000.005.9759,700.0047,900.00https://www.sec.gov/Archives/edgar/data/1012477/000110465919070217/0001104659-19-070217-index.htm
2019-11-18Geoffrey Michael GlassDirectorBuy15,000.004.9974,850.0047,900.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021887/0001567619-19-021887-index.htm
2020-08-12Geoffrey Michael GlassDirectorBuy6,500.007.7050,050.0054,400.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2019-12-12Sandra L HattenOfficerSell3,072.007.2322,210.5655,765.00https://www.sec.gov/Archives/edgar/data/1012477/000117911019012826/0001179110-19-012826-index.htm
2020-08-13Geoffrey Michael GlassDirectorBuy6,500.007.7650,440.0060,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009054/0001179110-20-009054-index.htm
2020-08-12Eric J EndeDirectorBuy15,000.007.76116,355.0062,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009024/0001179110-20-009024-index.htm
2020-08-13Eric J EndeDirectorBuy1,200.007.749,288.0064,100.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-08-28Geoffrey Michael GlassDirectorBuy4,800.006.7832,559.8465,700.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009461/0001179110-20-009461-index.htm
2020-08-13Eric J EndeDirectorBuy3,800.007.8029,640.0067,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009083/0001179110-20-009083-index.htm
2020-09-17Eric J EndeDirectorBuy17,000.005.7998,375.6084,900.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009877/0001179110-20-009877-index.htm
2019-11-15GREG J DIVISChief Executive OfficerBuy19,000.005.1397,470.0086,100.00https://www.sec.gov/Archives/edgar/data/1012477/000156761919021885/0001567619-19-021885-index.htm
2020-08-12Gregory J DivisChief Executive OfficerBuy13,000.007.78101,155.6099,100.00https://www.sec.gov/Archives/edgar/data/1012477/000117911020009023/0001179110-20-009023-index.htm